pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
689
stories
2h
Could we one day vaccinate against every cancer?
stat
6h
STAT+: Hospital and pharmaceutical prices are smothering America’s businesses
stat
6h
STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
stat
6h
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
fiercebiotech
9h
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
9h
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
10h
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
fiercebiotech
10h
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
10h
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
biospace
2d
EAK Distribution LLC Recalls HOME GROWN Green Sprouting Calabrese Broccoli Seeds, 8 oz, Heirloom Because of Possible Health Risk
fda recalls
2d
Frutas y Hortalizas del Sur S.A. Expands Recalls to Include Additional Lots of Great Value Frozen Organic Triple Berry Blend 10 OZ, Great Value Frozen Organic Blueberries 10 OZ and One Lot of Trader Joe’s Frozen Organic Mixed Berry Blend 12 OZ Because of Potential Contamination with E. coli O145
fda recalls
2d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
3d
Foghorn cuts 40% of workforce
biospace
3d
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
3d
STAT+: Lilly bypasses Australian pharmacies with DTC model
stat
3d
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
stat
3d
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
biospace
3d
‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipeline
fiercebiotech
3d
Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront
endpoints
3d
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
fiercebiotech
3d
Immunotherapy startup Adecto blames ‘risk-averse funding environment’ for closing down
fiercebiotech
3d
Top journal’s special issue on women’s health casts spotlight on menopause and pain
stat
3d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
3d
Sanofi, Regeneron broaden alliance to find their next Dupixent
biopharma dive
3d
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
3d
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
3d
Foghorn lays off 40% of staff after Lilly collaboration ends
biospace
3d
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
4d
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
biospace
4d
STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy
stat
← prev
page 1 of 23
next →
